Ignite Creation Date:
2024-05-06 @ 10:15 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03206931
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2021-09-16
First Post:
2017-06-29
Brief Title:
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Expanded Access to Provide Selitrectinib BAY2731954 for the Treatment of Cancers With a NTRK Gene Fusion
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene NTRK1 NTRK2 or NTRK3 gene fusion The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion including blood cancers who have previously received tropomyosin receptor kinase TRK inhibitor therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None